Limits...
Prognostic value of decreased microRNA-133a in solid cancers: a meta-analysis

View Article: PubMed Central - PubMed

ABSTRACT

Objective: Increasing evidence indicates that the decreased expression of microRNA-133a (miR-133a) may be correlated with poor survival for cancer patients. Thus, we performed this meta-analysis to evaluate the prognostic value of decreased miR-133a in solid cancers.

Methods: Eligible studies were gathered by searching on PubMed, Web of Science, and Embase. Using the STATA 12.0 software, the pooled hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) for total and subgroup analyses were calculated to investigate the possible correlation between decreased miR-133a and overall survival (OS) of patients with cancer.

Results: Ten studies were enrolled in this meta-analysis. The pooled result showed that decreased expression of miR-133a predicted poor OS in solid cancer patients (HR =1.62, 95% CI: 1.16–2.24, P=0.004). Compared with the total pooled HR, further analyses indicated that the subgroups of digestive system neoplasms (HR =1.73, 95% CI: 1.20–2.51, P=0.003), frozen tissue preservation (HR =1.89, 95% CI: 1.41–2.53, P<0.001), and multivariate analysis (HR =2.07, 95% CI: 1.42–3.02, P<0.001) exhibited stronger connection between decreased miR-133a expression and OS outcome.

Conclusion: This meta-analysis suggested that decreased miR-133a was associated with poor OS in patients with solid cancer. Because of the data in our study are limited, additional studies are required to verify the poor prognosis of decreased miR-133a in solid tumors.

No MeSH data available.


Flow diagram of the selection of eligible studies.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC5036562&req=5

f1-ott-9-5771: Flow diagram of the selection of eligible studies.

Mentions: The initial search identified 59 potentially relevant records. After the duplicates were removed, 28 records were preserved. By further reviewing, 21 studies were determined to be of acceptable relevance and assessed for eligibility. However, eleven of them were excluded due to without OS data. Finally, ten studies met the eligible criteria and were included in this meta-analysis.24–29,31–34 The flow diagram on the selection process is shown in Figure 1.


Prognostic value of decreased microRNA-133a in solid cancers: a meta-analysis
Flow diagram of the selection of eligible studies.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC5036562&req=5

f1-ott-9-5771: Flow diagram of the selection of eligible studies.
Mentions: The initial search identified 59 potentially relevant records. After the duplicates were removed, 28 records were preserved. By further reviewing, 21 studies were determined to be of acceptable relevance and assessed for eligibility. However, eleven of them were excluded due to without OS data. Finally, ten studies met the eligible criteria and were included in this meta-analysis.24–29,31–34 The flow diagram on the selection process is shown in Figure 1.

View Article: PubMed Central - PubMed

ABSTRACT

Objective: Increasing evidence indicates that the decreased expression of microRNA-133a (miR-133a) may be correlated with poor survival for cancer patients. Thus, we performed this meta-analysis to evaluate the prognostic value of decreased miR-133a in solid cancers.

Methods: Eligible studies were gathered by searching on PubMed, Web of Science, and Embase. Using the STATA 12.0 software, the pooled hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) for total and subgroup analyses were calculated to investigate the possible correlation between decreased miR-133a and overall survival (OS) of patients with cancer.

Results: Ten studies were enrolled in this meta-analysis. The pooled result showed that decreased expression of miR-133a predicted poor OS in solid cancer patients (HR =1.62, 95% CI: 1.16–2.24, P=0.004). Compared with the total pooled HR, further analyses indicated that the subgroups of digestive system neoplasms (HR =1.73, 95% CI: 1.20–2.51, P=0.003), frozen tissue preservation (HR =1.89, 95% CI: 1.41–2.53, P<0.001), and multivariate analysis (HR =2.07, 95% CI: 1.42–3.02, P<0.001) exhibited stronger connection between decreased miR-133a expression and OS outcome.

Conclusion: This meta-analysis suggested that decreased miR-133a was associated with poor OS in patients with solid cancer. Because of the data in our study are limited, additional studies are required to verify the poor prognosis of decreased miR-133a in solid tumors.

No MeSH data available.